Recent advances in cancer cell bionic nanoparticles for tumour therapy

• Published in: Journal of drug targeting Vol. 31; no. 10; p. 1065
• Main Authors: Jiang, Wanting, Lei, Yujing, Peng, Cheng, Wu, Donghai, Wu, Jing, Xu, Yiling, Xia, Xinhua
• Format: Journal Article
• Language: English
• Published: England 01.12.2023
• Subjects: Bionics; Drug Delivery Systems; Humans; Nanoparticles - therapeutic use; Neoplasms - drug therapy; Neoplasms - pathology; Phototherapy; nanoparticles; multimodal antitumour therapy; Tumour cells; bionic nanoparticles
• ISSN: 1029-2330
• DOI: 10.1080/1061186X.2023.2283838

Nanoparticle-based drug delivery systems have found extensive use in delivering oncology therapeutics; however, some delivery vehicles still exhibit rapid immune clearance, lack of biocompatibility and insufficient targeting. In recent years, bionanoparticles constructed from tumour cell membranes have gained momentum as tumour-targeting therapeutic agents. Cancer cell membrane-coated nanoparticles (CCMCNPs) typically consist of a drug-loaded nanoparticle core coated with cancer cell membrane. CCMCNPs retain homologous tumour cell surface antigens, receptors and proteins, and it has been shown that the modified nanoparticles exhibit better homologous targeting, immune escape and biocompatibility. CCMCNPs are now widely used in a variety of cancer treatments, including photothermal, photodynamic and sonodynamic therapies, chemotherapy, immunotherapy, chemodynamical therapy or other combination therapies. This article presents different therapeutic approaches using multimodal antitumour therapy-combination of two or more therapies that treat tumours synergistically-based on tumour cell membrane systems. The advantages of CCMCNPs in different cancer treatments in recent years are summarised, thus, providing new strategies for cancer treatment research.